Method for treating cannabinoid receptor related diseases with cannabinoid receptor ligands

1. A method for treating a disorder selected from the group consisting of inflammatory disorders, immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, and cardiovascular disorders in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound of formula (I)

or a pharmaceutically suitable salt or prodrug thereof, wherein

is absent or is a bond;

m and n are each independently 0, 1 or 2;

p is 1 or 2;

q and r are each independently 0 or 1;

s is 0, 1, 2, 3, or 4;

R 1 is selected from the group consisting of alkyl, alkoxyalkyl, alkylcarbonyl, cyano, cyanoalkyl, halo, haloalkyl, R 4 O 2 C—, R c R d NC(O)—, and R c R d NS(O) 2 —;

R 2 is selected from the group consisting of aryl, cycloalkyl, heteroaryl, heterocycle, —O(R h ), and R e R f N—;

R 3 is selected from the group consisting of alkyl, alkoxyalkyl, haloalkyl, hydroxyalkyl, R 5 —C(O)—, R 5 —C(═N—OR p )—, R 6 OC(O)—, R g R j NC(O)—, R 5 —S(O) 2 —, and R g R j NS(O) 2 —;

R 4 is selected from the group consisting of alkyl, arylalkyl, haloalkyl, heteroarylalkyl, and heterocyclealkyl;

R 5 , at each occurrence, is selected from the group consisting of alkyl, alkoxyalkyl, aryl, cycloalkyl, haloalkyl, heteroaryl, and heterocycle;

R 6 is selected from the group consisting of alkyl, arylalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclealkyl, and heteroarylalkyl;

R c and R d , at each occurrence, are each independently selected from the group consisting of hydrogen and alkyl, or R c and R d together with the nitrogen atom to which they are attached form a heterocyclic ring;

R e is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and alkylcarbonyl;

R f is selected from the group consisting of hydrogen and alkyl;

R g , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, heteroarylalkyl, heterocyclealkyl, and heterocyclealkyl;

R j , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, and haloalkyl;

R h is a cycloalkyl ring optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, haloalkyl, arylalkyl, heteroarylalkyl, cycloalkyl, and heterocyclealkyl; and

R p is selected from the group consisting of hydrogen and alkyl.